Figure 2.
ALK-TKI status, discontinuation reasons, and sites of progressive disease: (A) total cohort, (B) 2nd generation ALK-TKI, and (C) crizotinib. ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.